A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting · Phase 2 · NCT03314181
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $72,667
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 156
About the trial
- Sponsor
- AbbVie (with Janssen Research & Development, LLC)
- Tested
- Dexamethasone (drug), Daratumumab (drug), Venetoclax (drug), Bortezomib (drug)
- Dates
- Started 2018-04-02; completion 2031-05
- Results posted
- Not yet
This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R) multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd); Part 3 includes participants with t(11;14) positive R/R multiple myeloma w…
From ClinicalTrials.gov, last updated 2025-08-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $72,667 in research payments for this study in 2025 (25 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rachid C. Baz, MD Hematology & Oncology · Tampa, FL
- Jonathan L. Kaufman, M.D. Medical Oncology · Atlanta, GA
- Jacob P. Laubach, M.D. Medical Oncology · Boston, MA
- Cristina Gasparetto, M.D. Infectious Disease · Durham, NC
- Eva Medvedova, M.D. Hematology · Portland, OR
- Andrew J. Cowan, M.D. Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Washington Medical Ctr, WA $20,058
- Moffitt Cancer Center $18,226
- Emory University Hospital, GA $16,704
- Ohsu Hospital and Clinics, OR $15,595
- Duke University $1,096
- Dana Farber Cancer Institute $989
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.